Skip to main content
SpringerLink
Log in

Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and Objective

Chronic obstructive pulmonary disease (COPD), a progressive lung disorder associated with decline of respiratory function, affects 10.2% of Spanish adults (40–80 years of age). This study aimed to assess the cost-effectiveness of two fixed-dose combinations of long-acting muscarinic antagonist and long-acting β2-agonist therapies for COPD, with Spanish National Health System perspective.

Methods

A Markov model with five health states based on severity levels defined by GOLD 2010 criteria was used to simulate in monthly cycles the evolution along a 5-year period of a cohort of moderate-to-severe COPD patients, treated with aclidinium–formoterol (ACL/FF) 400/12 µg or tiotropium–olodaterol (TIO/OLO) 5/5 µg fixed-dose combinations. Clinical data on lung-function improvement were obtained from a network meta-analysis and applied to mean baseline forced-expiratory-volume in 1 s (FEV1) for the first 24-weeks period. Natural history for lung-function decline (41 ml/year) was applied until the end of simulation. Risk of exacerbation and pneumonia occurrence were considered. Pharmaceutical costs were calculated with dosages according to indication and public ex-factory prices. The health state-specific disease management and event costs, and utilities were derived from the literature. Total costs (€ 2016) and benefits [life-year-gained (LYG) and quality-adjusted-life-year (QALY)] were discounted (3.0% yearly). Sensitivity analyses were performed.

Results

Both therapies provided the same outcomes (4.073 LYG and 2.928 QALY) at 5-year period. ACL/FF 400/12 µg provided marginally lower costs (€ − 332) compared to TIO/OLO 5/5 µg.

Conclusion

ACL/FF 400/12 µg was a cost-saving therapy in patients with moderate-to-severe COPD in Spain, and provided equivalent effects compared to TIO/OLO 5/5 µg.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2014. http://www.goldcopd.org/. Accessed 28 Jul 2016.

  2. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J. 2003;41(Suppl):S46–53.

    Article  Google Scholar 

  3. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64(10):863–8.

    Article  PubMed  CAS  Google Scholar 

  5. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for chronic obstructive pulmonary disease (GOLD). Workshop summary. Am J Respir Crit Care Med. 2013;187:347–65.

    Article  PubMed  CAS  Google Scholar 

  6. Ministerio de Sanidad y Política Social. Plan de Calidad para el Sistema Nacional de Salud. Estrategia en EPOC del Sistema Nacional de Salud. Sanidad 2009. Ministerio de Sanidad y Política Social. http://www.msc.es/organizacion/sns/planCalidadSNS/docs/EstrategiaEPOCSNS.pdf. Accessed 05 Apr 2017.

  7. Sicras A, Huerta A, Navarro R, Ibañez J. Uso de recursos y costs asociados a las exacerbaciones de enfermedad pulmonar obstructive crónica: estudio retrospective de base poblacional. Semergen. 2014;40(4):189–97.

    Article  PubMed  CAS  Google Scholar 

  8. Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med. 2011;9:7.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012;7:457–94.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Miravitlles M, Soler-Cataluña JJ, Calle M, Guía Española de la EPOC (GesEPOC), et al. (GesEPOC). Tratamiento farmacológico de la EPOC estable. Arch Bronconeumol. 2012;48(7):247–57.

    Article  PubMed  Google Scholar 

  11. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Banerji D, Mahler DA, Hanania NA. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. Expert Rev Respir Med. 2016;10(7):767–80.

    Article  PubMed  CAS  Google Scholar 

  13. Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–96.

    Article  PubMed  Google Scholar 

  14. Di Marco F, Santus P, Scichilone N, et al. Symptom variability and control in COPD: advantages of dual bronchodilation therapy. Respir Med. 2017;125:49–56.

    Article  PubMed  Google Scholar 

  15. Centro Vasco de Información de Medicamentos. Nuevos medicamentos inhalados en la EPOC: ¿qué nos aportan?. Boletín de información farmacoterapéutica de la comarca (INFAC). 2015;23(9). http://www.euskadi.eus/contenidos/informacion/cevime_infac_2015/es_def/adjuntos/INFAC_Vol_23_n_9_nuevos_medicamentos_inhalados.pdf. Accessed 06 Apr 2017.

  16. Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in sympomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34(11):2518–33.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis. 2013;7(6):311–9.

    Article  PubMed  CAS  Google Scholar 

  18. Huisman EL, Cockle SM, Ismaila AS, Karabis A, Punekar YS. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:1863–81.

    PubMed  PubMed Central  CAS  Google Scholar 

  19. Schlueter M, Gonzalez-Rojas N, Baldwin M, Groenke L, Voss F, Reason T. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10(2):89–104.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2016;10(5):391–401.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017;12:997–1008.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Miravitlles M, Gáldiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. Int J Chron Obstruct Pulmon Dis. 2016;11:123–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15(6):796–803.

    Article  PubMed  Google Scholar 

  24. National Clinical Guideline Centre (2010). Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. http://guidance.nice.org.uk/CG101/Guidance/pdf/. Accessed 30 Aug 2016.

  25. López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-Junoy J. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11(5):513–20.

    Article  PubMed  Google Scholar 

  26. Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ. 2007;8(2):123–35.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J. 2001;17(5):928–33.

    Article  PubMed  CAS  Google Scholar 

  28. Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. D’Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Casanova C, Marin JM, Martinez-Gonzalez C, et al. COPD history assessment in SpaiN (CHAIN) Cohort. New GOLD classification: longitudinal data on group assignment. Respir Res. 2014;15:3.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Statistic National Institute. Instituto Nacional de Estadísitica. http://www.ine.es. Accessed 26 Aug 2016.

  33. Tashkin DP, Celli B, Senn S, UPLIFT Study Investigators, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.

    Article  PubMed  CAS  Google Scholar 

  34. Ramos M, Haughney J, Henry N, Lindner L, Lamotte M. Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD. Clin Outc Res. 2016;8:445–56.

    Google Scholar 

  35. Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjermer L. Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord–Trøndelag Study. Eur Respir J. 2001;18(5):770–9.

    Article  PubMed  CAS  Google Scholar 

  36. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Mak. 1994;14(1):52–8.

    Article  CAS  Google Scholar 

  37. Karabis A, Mocarski M, Eijgelshoven I, Bergman G. Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years. Clin Outc Res. 2014;6:175–85.

    Google Scholar 

  38. Oostenbrink JB, Rutten-van Mölken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health. 2005;8(1):32–46.

    Article  PubMed  Google Scholar 

  39. Boutou AK, Shrikrishna D, Tanner RJ, et al. Lung function indices for predicting mortality in COPD. Eur Respir J. 2013;42(3):616–25.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006;130(4):1117–28.

    Article  PubMed  Google Scholar 

  41. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD. 2004;1(2):303–12.

    Article  PubMed  Google Scholar 

  42. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, UPLIFT Investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–8.

    Article  PubMed  CAS  Google Scholar 

  43. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–37.

    Article  PubMed  CAS  Google Scholar 

  44. Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res. 2000;9(5):521–7.

    Article  PubMed  CAS  Google Scholar 

  45. Consejo General de Colegios Oficiales de Farmacéuticos. Base de datos del Conocimiento Sanitario-Bot Plus 2.0 [Health Knowledge database-Bot Plus 2.0]. https://botplusweb.portalfarma.com/. Accessed 28 June 2016.

  46. Ministerio de Sanidad, Servicios Sociales e Igualdad. Relación informativa de medicamentos afectados por las deducciones establecidas en el Real Decreto Ley 8/210 de 20 de Mayo por el que se adoptan medidas extraordinarias para la reducción del déficit público. [Internet]. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2010. https://www.msssi.gob.es/profesionales/farmacia/pdf/DeduccionesAgosto2016.pdf. Accessed 28 Aug 2016.

  47. Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica de Spiolto® [Internet]. Madrid: Agencia Española de Medicamentos y Productos Sanitarios; 2013. https://www.aemps.gob.es/cima/pdfs/es/ft/79967/FichaTecnica_79967.html.pdf. Accessed 27 June 2016.

  48. Agencia Europea de Medicamentos. Ficha técnica de Duaklir®. Londres: Agencia Europea de Medicamentos; 2011. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003745/WC500178413.pdf. Accessed 27 June 2016.

  49. Miravitlles M, Murio C, Guerrero T, Gisbert R. Decisiones sobre Antibioticoterapia y Farmacoeconomía en la EPOC. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002;121(5):1449–55.

    Article  PubMed  Google Scholar 

  50. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest. 2003;123(3):784–91.

    Article  PubMed  Google Scholar 

  51. Oblikue Consulting. Base de datos de costes sanitarios eSalud [eSalud Health Cost database] [Internet]. http://www.oblikue.com/bbdcostes/. Accessed 29 June 2016.

  52. Almagro P, Martinez-Camblor P, Soriano JB, et al. Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients:the COCOMICS study. PLoS One. 2014;9(2):e89866.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Scanlon PD, Connett JE, Waller LA, et al. Lung Health Study Research Group. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161(2 Pt 1):381–90.

    Article  PubMed  CAS  Google Scholar 

  54. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417–28.

    Article  PubMed  Google Scholar 

  55. Eklund O, Afzal F, Borgström F, Ojanguren ME, Crespo C, Baldwin M. Cost-effectiveness of tiotropium vs glycopyrronium in moderate to very severe Copd in Spain. Value Health. 2015;18(7):A501.

    Article  PubMed  CAS  Google Scholar 

  56. Tebboth A, Ternouth A, Gonzalez-Rojas N. UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clin Outc Res. 2016;8:667–74.

    Google Scholar 

  57. Laramée P, Millier A, Brodtkorb TH, et al. A comparison of Markov and discrete-time microsimulation approaches: simulating the avoidance of alcohol-attributable harmful events from reduction of alcohol consumption through treatment of alcohol dependence. Clin Drug Investig. 2016;36(11):945–95.

    Article  PubMed  Google Scholar 

  58. De Miguel Díez J. Farmacoeconomía en el asma y en la EPOC. Arch Bronconeumol. 2005;41(5):239–41.

    Google Scholar 

  59. Miravitlles M, Figueras M. El coste de la enfermedad pulmonar constructiva crónica en España. Opciones para una optimización de recursos. Arch Bronconeumol. 2001;37:388–93.

    Article  PubMed  CAS  Google Scholar 

  60. Bhardwaj SS, Camacho F, Derrow A, Fleischer AB Jr, Feldman SR. Statistical significance and clinical relevance: the importance of power in clinical trials in dermatology. Arch Dermatol. 2004;140(12):1520–3.

    Article  PubMed  Google Scholar 

  61. Van Dijk WD, van den Bemt L, van Weel C. Megatrials for bronchodilators in chronic obstructive pulmonary disease (COPD) treatment: time to reflect. J Am Board Fam Med. 2013;26(2):221–4.

    Article  PubMed  Google Scholar 

  62. Gillissen A, Buhl R, Kardos P, Puhan M, Rabe KF, Rothe T, Sauer R, Welte T, Worth H, Menz G. Trial end-point in chronic obstructive pulmonary disease(COPD): minimal clinically important difference. Pneumologie. 2008;62(3):149–55.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Astra Zeneca, Madrid, Spain

    Margarita Capel

  2. Pharmacoeconomics and Outcomes Research Iberia (PORIB), Madrid, Spain

    María Mareque & Itziar Oyagüez

  3. Servicio Neumología, Hospital 12 de Octubre, Madrid, Spain

    Carlos José Álvarez

  4. Astra Zeneca, Cambridge, UK

    Leandro Lindner

Authors
  1. Margarita Capel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María Mareque
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlos José Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leandro Lindner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Itziar Oyagüez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to María Mareque.

Ethics declarations

Funding

This study was funded by AstraZeneca Spain.

Conflicts of interest

IO and MM are currently employed at PORIB, a consultant company specialized in economic evaluation of health interventions, which received financial support from AstraZeneca for the development of this study. CJA has received honoraria from Pharmacoeconomics and Outcomes Research Iberia for advocacy tasks related to this project. MC is an employee of AstraZeneca, Spain. LL is an employee of AstraZeneca, UK.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Capel, M., Mareque, M., Álvarez, C.J. et al. Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment. Clin Drug Investig 38, 611–620 (2018). https://doi.org/10.1007/s40261-018-0646-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-018-0646-0

Search

Navigation